Intestinal Pseudo-Obstruction Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The intestinal pseudo-obstruction treatment market size has grown strongly in recent years. It will grow from $23.46 billion in 2024 to $24.87 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increased recognition and diagnosis, advancements in medical imaging, advancements in gastrointestinal motility testing, global healthcare access.

The intestinal pseudo-obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $30.9 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include advanced gastrointestinal motility testing, immunomodulatory therapies, nutritional interventions, data analytics and ai.

The increasing prevalence of Parkinson's disease is anticipated to be a significant driver for the expansion of the intestinal pseudo-obstruction (IPO) treatment market in the foreseeable future. Parkinson's disease is a neurodegenerative condition primarily affecting dopamine-producing neurons in the substantia nigra region of the brain. The heightened incidence of IPO in individuals with Parkinson's disease is attributed to its impact on the enteric nervous system, leading to gastrointestinal dysmotility, potentially resulting in conditions like megacolon or acute colonic pseudo-obstruction. For instance, in December 2022, according to the Parkinson's Foundation, a U.S.-based non-profit organization, there has been a notable increase in Parkinson's disease diagnoses, with approximately 90,000 Americans being identified annually, representing a substantial 50% surge from previous estimates. Moreover, it is projected that by 2030, the global population with Parkinson's disease will reach 1.2 million. Consequently, the escalating cases of Parkinson's disease serve as a driving force for the growth of the intestinal pseudo-obstruction treatment market.

The rising number of cancer cases is expected to drive the growth of the intestinal pseudo-obstruction (IPO) treatment market in the coming years. Cancer is a disease where certain cells in the body grow uncontrollably and spread to other areas. Factors such as sedentary lifestyles, poor eating habits, and tobacco use increase the risk of cancer. In the treatment of intestinal pseudo-obstruction (IPO) related to cancer, managing the underlying cancer is a key approach, which can help alleviate or resolve the gastrointestinal symptoms associated with pseudo-obstruction. For example, in October 2022, Macmillan Cancer Support, a UK-based non-profit organization, reported that around 3 million people in the UK are currently living with cancer, with projections suggesting this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the growing incidence of cancer is fueling the expansion of the intestinal pseudo-obstruction (IPO) treatment market.

The increasing demand for personalized medicine is expected to drive the growth of the intestinal pseudo-obstruction (IPO) treatment market in the future. Personalized medicine leverages genetic information to tailor treatments to individual patients. The growing demand for this approach is driven by advancements in genomics, biotechnology, and the rising awareness of genetic testing and precision healthcare. Personalized medicine offers customized treatments for intestinal pseudo-obstruction, taking into account a patient’s unique genetic makeup and lifestyle, which enhances symptom management and the effectiveness of therapy. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approvals in 2022. Therefore, the growing demand for personalized medicine is fueling the expansion of the intestinal pseudo-obstruction (IPO) treatment market.

In May 2023, Ironwood Pharmaceuticals, a pharmaceutical company headquartered in the United States, completed the acquisition of VectivBio Holding AG for an undisclosed sum. This strategic move is poised to bolster Ironwood's innovation capabilities and expand its portfolio, ultimately reshaping the benchmark for care in the field of gastrointestinal (GI) medicine. The acquisition will also propel advancements in the treatment of GI disorders, with VectivBio Holding AG, a clinical-stage biotechnology company based in Switzerland, specializing in the treatment of severe and rare gastrointestinal conditions, including Intestinal Pseudo-Obstruction (IPO).

Major companies operating in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddy's Laboratories Ltd., Allergan PLC, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.

North America was the largest region in the intestinal pseudo-obstruction treatment market in 2024. The regions covered in intestinal pseudo-obstruction (IPO) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the intestinal pseudo-obstruction (IPO) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intestinal pseudo-obstruction (IPO) treatment market consists of revenues earned by providing entities by providing surgical interventions, decompression and nutrition support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal pseudo-obstruction (IPO) treatment market also includes sales of narcotics, laxatives and pro-kinetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Intestinal pseudo-obstruction (IPO) treatment addresses a rare gastrointestinal motility disorder exhibiting symptoms akin to a mechanical bowel obstruction, even in the absence of a physical blockage. The goals of treating intestinal pseudo-obstruction involve symptom relief, enhancement of intestinal motility, complication management, and overall improvement in quality of life.

The primary drug classes encompassed in IPO treatment comprise antibiotics, antidepressants, and antidiarrheals. Antibiotics represent a potent category of medications employed for combating bacterial infections in both human and animal patients. Diverse treatment modalities, such as medication, surgery, dietary adjustments, decompression, and others, are administered via various routes, including oral, intravenous, among others. Multiple diagnostic approaches, including physical examinations, biopsies, blood tests, gastric emptying tests, imaging studies, among others, are utilized by a range of end users, including clinics, hospitals, and other healthcare facilities.

The intestinal pseudo-obstruction market research report is one of a series of new reports that provides intestinal pseudo-obstruction market statistics, including intestinal pseudo-obstruction industry global market size, regional shares, competitors with a intestinal pseudo-obstruction market share, detailed intestinal pseudo-obstruction market segments, market trends and opportunities and any further data you may need to thrive in the intestinal pseudo-obstruction industry. This intestinal pseudo-obstruction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.